{
    "nctId": "NCT04034823",
    "briefTitle": "KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer",
    "officialTitle": "KN035, a Single Domain PD-L1 Subcutanuous Injection Antibody, in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "HER2-positive Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 59,
    "primaryOutcomeMeasure": "Objective response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Written informed consent\n* Female subjects with age 18 to 70 (inclusive) years at the time of consent\n* LVEF \u226550% at baseline\n* ECOG performance status of 0-1\n* Have not received 1L treatment for recurrent or metastatic breast cancer\n* Adequate organ function\n\nExclusion Criteria:\n\n* History of exposure to the cumulative doses of doxorubicin \\> 400 mg / m2 or equivalent\n* History of autoimmune diseases\n* Active brain metastasis\n* Concurrent diseases that compromise patient's safety",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}